REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot173410.32687/1561-5936-2024-28-4-367-370Original ArticleAssessment of the impact of «evergreening patients» on the budget segment of the Russian pharmaceutical marketDenisovaMaria N.denisovamn@gmail.comNadelyaevaIrina I.nadirina@mail.ruN. A. Semashko National Research Institute of Public Health, Moscow, Russian FederationPetrovsky National Research Center of Surgery, Moscow, Russia15122024436737015102025Copyright © 2024,2024The article presents the results of a study conducted to identify opportunities for budget savings in healthcare in federal programs. A set of methods was used in the study: bibliographic, analytical and comparative analysis. The IQVIA Database was used as source of information — data on purchases in the «budget segment» in hospitals and for privileged categories of citizens (federal and regional benefits). Based on an analysis of a sample of 11 INNs with signs of secondary patents, it is shown that entering the generics market (in the absence of secondary patents) will save the budget 82.5 billion rubles over three years. This corresponds to an average annual budget savings of 27.5 billion rubles, which is equivalent to financing the federal project «Combating diabetes mellitus» for the period from 2024 to 2026.pharmaceutical marketmedicinesdrugpatentbudgetgovernment programsfederal projectфармацевтический рыноклекарственные препаратыпатентбюджетгосударственные программыфедеральный проект1.Woodruff R. C., Tong X., Khan S. S. et al. Trends in cardiovascular disease mortality rates and excess deaths, 2010–2022. Am. J. Prev. Med. 2024;66(4):582–589.2.Kaprin A. D., Starinsky V. V., Shakhzadova A. O. (eds.). The state of oncological care for the population of Russia in 2022. Moscow; 2022. 239 p. (In Russ.)3.Feldman R. May your drug price be evergreen. J. Law Biosci. 2018;5(3):590–647.4.Mayor S. Insulin has never become a cheap generic drug in the US because of companies' small changes to «evergreen» the patent. BMJ. 2015;350:15–35.5.Hitchings A. W., Baker E. H., Khong T. K. Making medicines evergreen. BMJ. 2012;345:e7941. DOI: 10.1136/bmj.e79416.Orlova A. I. // Patent strategies in pharmaceuticals: «patent gardening». Journal of the Court of Intellectual Property Rights. 2019;(26):83–89.7.Downing N. S., Aminawung J. A., Shah N. D. et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA. 2014;311(4):368–377.8.Psaty B. M., Meslin E. M., Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA. 2012;307(23):2491–2492.